MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

CNS Drugs · 2018 · PMC6061426 · PMID 29808469

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an interesting trendno p-value reported

An interesting trend favoring MD1003 was observed in the subgroup of patients with PON.

also in 1,783 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.